NiKang Therapeutics , a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs and Hansoh Pharmaceutical Group Company, a China and US based leading biopharmaceutical company, have announced an exclusive collaboration and license agreement for the development and commercialization of NKT2152, for the treatment of cancer in Greater China, including Mainland China, Hong Kong, Macau and Taiwan.

Under the terms of the agreement, NiKang will receive an upfront cash payment of $15 million and will be eligible to receive up to $203 million in potential development, regulatory and sales-based milestone payments, and tiered royalties.

Hansoh will be responsible for all the development costs for NKT2152 in Greater China and will receive the exclusive rights to develop and commercialize NKT2152 in the region.

NKT2152 is a small molecule that inhibits HIF2α. It is currently in a phase 1/2 dose escalation and expansion trial (NCT05119335). This trial is designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and clinical activity in patients with advanced clear cell renal cell carcinoma (ccRCC).